Prenetics Global (PRE) investor relations material

Executive summary

• Q1 2026 revenue reached $36M, with IM8 contributing $33.8M, up 334% year-over-year and 23% sequentially, reflecting transformation into a high-growth consumer health leader focused on IM8's global expansion and clinical validation.

• IM8's monthly revenue hit $16.7M in May 2026, implying $200M in annualized recurring revenue.

• Divested non-core assets and digital holdings, redeploying $116M and generating $41.3M in cash to focus on core consumer health and prevention businesses.

• IM8 is positioned as a premium, clinically-backed supplement brand with rapid ARR and subscriber growth.

• Loss for the period was $23.1M, mainly due to non-cash, non-operating items including unrealized fair-value losses on digital assets and warrant liabilities.

Financial highlights

• Q1 2026 revenue reached $36M, up 334% year-over-year; $33.8M from IM8 segment, with CircleDNA contributing $2.2M.

• Gross margin for Q1 2026 was 64.8%, with IM8 segment at 64.3%, up from 60% in Q4 2025 due to manufacturing efficiencies.

• Adjusted EBITDA for Q1 2026 was ($5.6M), improved from an $11.1M loss in Q1 2025, reflecting continued investment in growth.

• Cash and holdings as of March 31, 2026, totaled $147M, with zero debt; combined cash, financial assets, and escrow balances were ~$139.7M as of May 31, 2026.

• Share repurchase program authorized for $40M, with $19M spent as of May 2026.

Outlook and guidance

• FY 2026 revenue guidance raised to $190-210M (previously $180-200M), with Q2 2026 projected revenue of $46-48M, $44-46M from IM8.

• May 2026 ARR reached $200M, with monthly revenue of $16.7M.

• Management invested $2.75M in personal capital.